RGNXREGENXBIO Inc.
Price
-34%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth steady, the market against it.
Charts
As reported to the SEC, without any scoring.
REGENXBIO Inc. (RGNX) reported revenue of $108M in Q2 2026 (quarter ended Jun 30, 2026), up 406% from the same quarter a year earlier. That came with net income of $23M (21% of revenue). For the full year FY2025, revenue was $170M (+105% year on year) and net income −$194M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC (together with Sarepta Therapeutics, Inc., “Sarepta”) and Catalent …Material agreement entered · Form 8-K
- Aug 25, 2026On August 25, 2026, the Board of Directors (the “Board”) of REGENXBIO Inc. (the “Company”), elected Gregory Ciongoli as a Class II director of the Company effective immediately.Director or officer change · Form 8-K
- Aug 24, 2026On August 24, 2026, the Company announced that it received communication from the FDA that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for MPS II was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 BLA in the near term.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.